Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (SNN) will launch ALLEVYN COMPLETE CARE foam dressing and RENASYS EDGE negative pressure wound therapy at EWMA, Bremen, May 6-8, 2026.
ALLEVYN COMPLETE CARE features a five-layer design with ExuLOCK, ExuMASK change indicator and ShearDEFENSE. RENASYS EDGE is a lightweight, modular tNPWT pump reporting improved outcomes and an average 88% therapy-session patient compliance.
Smith+Nephew (NYSE:SNN) reported 5-year randomized trial results showing the CARTIHEAL AGILI-C implant delivered higher KOOS scores versus standard care through 60 months with superior pain relief and functional gains. The implant is FDA-approved, commercially available in the US, and received a Category I CPT code effective Jan 1, 2027.
Results were comparable for patients with and without osteoarthritis, and clinicians reported roughly twice the pain reduction versus debridement or microfracture.
Smith+Nephew (NYSE:SNN) reported randomized controlled trial results showing the REGENETEN Bioinductive Implant halved early post‑operative recovery times versus traditional suture anchor repair for partial‑thickness rotator cuff tears. Driving: 2.3 vs 5.1 weeks; office work: 1.7 vs 3.6 weeks; household chores: 3.8 vs 8.4 weeks (all p≤0.009).
The study found better quality of life at 6 weeks and 3 months and high tendon healing rates at 12 months comparable to standard repair; rehabilitation protocols differed between groups.
Smith+Nephew (NYSE:SNN) launched ALLEVYN COMPLETE CARE Foam Dressing on March 10, 2026, a five‑layer dressing designed for wound management and pressure injury prevention. It claims >99% bacterial exclusion, up to 93% mechanical energy absorption, >65% pressure‑injury risk reduction, longer wear times, and staged international rollout beginning in the US with wider European availability in 2026.
Smith+Nephew (NYSE:SNN) will showcase handheld robotics, digital planning and trauma/extremities implants at AAOS 2026 in New Orleans, March 3-6, 2026, Booth #839.
Highlights include the CORI handheld robotics ecosystem and new CORI SHOULDER cases, EVOS plating, TRIGEN MAX tibial nailing, ASC enterprise solutions and new distribution partnerships.
Smith+Nephew (NYSE:SNN) will showcase a comprehensive rotator cuff repair portfolio at AAOS 2026 in New Orleans, featuring the newly acquired Tendon Seam Repair System and the REGENETEN Bioinductive Implant.
Highlights: Tendon Seam has 510(k) clearance (2023); REGENETEN has >250,000 procedures since 2014; AAOS issued a Strong Recommendation for bioinductive implants to lower re-tear rates.
Smith+Nephew (NYSE:SNN) has signed an exclusive US distribution agreement with RMR Ortho to add the A’TOMIC™ Nitinol Fixation System to its Trauma, Foot & Ankle and Hand & Wrist portfolio. The system uses nitinol for active compression aiming to improve implant integrity and patient comfort. The partnership leverages Smith+Nephew’s US commercial scale to expand surgeon access and deepen engagement.
Smith+Nephew reported $5.8 billion in annual sales for 2024 and will distribute A’TOMIC across key US territories.
Smith+Nephew (SNN) signed a distribution agreement with SI-BONE to add the iFuse TORQ portfolio, expanding offerings for percutaneous pelvic fracture fixation and sacroiliac joint fusion. The iFuse TORQ TNT has FDA Breakthrough Device Designation and is NTAP-eligible, potentially adding up to $4,136 per procedure in reimbursement.
The deal grants Smith+Nephew access to SI-BONE’s sales channel and aims to deepen surgeon engagement in high-frequency trauma procedures.
Smith+Nephew (NYSE:SNN) has completed the acquisition of Integrity Orthopaedics, adding the Tendon Seam™ rotator cuff repair (RCR) system to its sports medicine shoulder portfolio.
Tendon Seam™ features patented microanchors, continuous suture and an integrated instrument, received 510(k) clearance in 2023, and is available in the US. Smith+Nephew positions Tendon Seam™ alongside its REGENETEN bioinductive implant to offer combined biomechanical and biological RCR solutions. The release cites ~500,000 annual US RCR procedures and historical re‑tear rates of 20–40%, while noting early clinical experience showing low re‑tear rates and shorter procedures.
Smith+Nephew (NYSE:SNN) published a comparative real-world analysis of single-use negative pressure wound therapy (sNPWT) using >22,000 patients from the Premier PINC AI healthcare database. The study reports that PICO sNPWT (-80 mmHg) produced materially better outcomes versus Prevena -125 mmHg in orthopedic (17,000+ patients) and cardiovascular (5,000+ patients) surgery.
Key quantified findings: 57.8% and 63.9% relative reductions in wound dehiscence risk, shorter hospital length of stay (cardio 6.33 vs 6.86 days; ortho 2.43 vs 3.10 days), and index/30–90 day admission cost reductions ranging ~13%–22% (all p-values reported).